Proteins > Purine nucleoside phosphorylase
Page last updated: 2024-08-07 15:31:06
Purine nucleoside phosphorylase
A purine nucleoside phosphorylase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00491]
Synonyms
PNP;
EC 2.4.2.1;
Inosine phosphorylase;
Inosine-guanosine phosphorylase
Research
Bioassay Publications (26)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 4 (15.38) | 18.7374 |
| 1990's | 7 (26.92) | 18.2507 |
| 2000's | 10 (38.46) | 29.6817 |
| 2010's | 5 (19.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Compounds (23)
Drugs with Inhibition Measurements
Drugs with Activation Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| forodesine | Homo sapiens (human) | Kd | 0.0001 | 1 | 1 |
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| guanosine | Homo sapiens (human) | Km | 83.0000 | 1 | 1 |
| inosine | Homo sapiens (human) | Km | 395.0000 | 2 | 2 |
| 8-bromoguanosine | Homo sapiens (human) | Km | 9,400.0000 | 1 | 1 |
| 8-aminoguanosine | Homo sapiens (human) | Km | 31,000.0000 | 1 | 1 |
The transition to magic bullets - transition state analogue drug design.MedChemComm, , Dec-01, Volume: 9, Issue:12, 2018
Nucleosides. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase.Journal of medicinal chemistry, , Apr-16, Volume: 36, Issue:8, 1993
The transition to magic bullets - transition state analogue drug design.MedChemComm, , Dec-01, Volume: 9, Issue:12, 2018
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-thJournal of medicinal chemistry, , May-01, Volume: 35, Issue:9, 1992
The transition to magic bullets - transition state analogue drug design.MedChemComm, , Dec-01, Volume: 9, Issue:12, 2018
Nucleosides. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase.Journal of medicinal chemistry, , Apr-16, Volume: 36, Issue:8, 1993
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.Journal of medicinal chemistry, , 09-26, Volume: 62, Issue:18, 2019
The transition to magic bullets - transition state analogue drug design.MedChemComm, , Dec-01, Volume: 9, Issue:12, 2018
Exploring new inhibitors of Plasmodium falciparum purine nucleoside phosphorylase.European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010
Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part II.Bioorganic & medicinal chemistry letters, , May-15, Volume: 19, Issue:10, 2009
Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase.Journal of medicinal chemistry, , Feb-26, Volume: 52, Issue:4, 2009
Immucillins in custom catalytic-site cavities.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 18, Issue:22, 2008
Simplified analogues of immucillin-G retain potent human purine nucleoside phosphorylase inhibitory activity.Journal of medicinal chemistry, , Oct-05, Volume: 49, Issue:20, 2006
Targeting the polyamine pathway with transition-state analogue inhibitors of 5'-methylthioadenosine phosphorylase.Journal of medicinal chemistry, , Jun-03, Volume: 47, Issue:12, 2004
8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.Journal of medicinal chemistry, , Jan-02, Volume: 46, Issue:1, 2003
Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.Journal of medicinal chemistry, , Jul-17, Volume: 46, Issue:15, 2003
The transition to magic bullets - transition state analogue drug design.MedChemComm, , Dec-01, Volume: 9, Issue:12, 2018
Structural basis for selective inhibition of purine nucleoside phosphorylase from Schistosoma mansoni: kinetic and structural studies.Bioorganic & medicinal chemistry, , Feb-15, Volume: 18, Issue:4, 2010
Nucleosides. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase.Journal of medicinal chemistry, , Apr-16, Volume: 36, Issue:8, 1993
Inhibitors of human purine nucleoside phosphorylase. Synthesis, purine nucleoside phosphorylase inhibition, and T-cell cytotoxicity of 2,5-diaminothiazolo[5,4-d]pyrimidin-7(6H)-one and 2,5-diaminothiazolo[4,5-d]pyrimidin-7(6H)-one. Two thio isosteres of 8Journal of medicinal chemistry, , Volume: 29, Issue:9, 1986
Synthesis of 8-amino-3-deazaguanine via imidazole precursors. Antitumor activity and inhibition of purine nucleoside phosphorylase.Journal of medicinal chemistry, , Volume: 29, Issue:10, 1986
The transition to magic bullets - transition state analogue drug design.MedChemComm, , Dec-01, Volume: 9, Issue:12, 2018
Guanine, pyrazolo[3,4-d]pyrimidine, and triazolo[4,5-d]pyrimidine (8-azaguanine) phosphonate acyclic derivatives as inhibitors of purine nucleoside phosphorylase.Journal of medicinal chemistry, , Feb-16, Volume: 39, Issue:4, 1996
[[(Guaninylalkyl)phosphinico]methyl]phosphonic acids. Multisubstrate analogue inhibitors of human erythrocyte purine nucleoside phosphorylase.Journal of medicinal chemistry, , Mar-17, Volume: 38, Issue:6, 1995
9-[(Phosphonoalkyl)benzyl]guanines. Multisubstrate analogue inhibitors of human erythrocyte purine nucleoside phosphorylase.Journal of medicinal chemistry, , Oct-29, Volume: 36, Issue:22, 1993
Structure-based design of inhibitors of purine nucleoside phosphorylase. 3. 9-Arylmethyl derivatives of 9-deazaguanine substituted on the methylene group.Journal of medicinal chemistry, , Nov-26, Volume: 36, Issue:24, 1993
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.Journal of medicinal chemistry, , 09-26, Volume: 62, Issue:18, 2019
The transition to magic bullets - transition state analogue drug design.MedChemComm, , Dec-01, Volume: 9, Issue:12, 2018
Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase.Journal of medicinal chemistry, , Feb-26, Volume: 52, Issue:4, 2009
Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.Journal of medicinal chemistry, , Jul-17, Volume: 46, Issue:15, 2003
8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.Journal of medicinal chemistry, , Jan-02, Volume: 46, Issue:1, 2003
Pharmacological urate-lowering approaches in chronic kidney disease.European journal of medicinal chemistry, , Mar-15, Volume: 166, 2019
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.Journal of medicinal chemistry, , 09-26, Volume: 62, Issue:18, 2019
The transition to magic bullets - transition state analogue drug design.MedChemComm, , Dec-01, Volume: 9, Issue:12, 2018
Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase.Journal of medicinal chemistry, , Feb-26, Volume: 52, Issue:4, 2009
A beta-fluoroamine inhibitor of purine nucleoside phosphorylase.Journal of medicinal chemistry, , Sep-25, Volume: 51, Issue:18, 2008
Azetidine based transition state analogue inhibitors of N-ribosyl hydrolases and phosphorylases.Journal of medicinal chemistry, , Feb-28, Volume: 51, Issue:4, 2008
Immucillins in custom catalytic-site cavities.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 18, Issue:22, 2008
Benzimidazole-4,7-diones as inhibitors of protozoal (Toxoplasma gondii) purine nucleoside phosphorylase.Bioorganic & medicinal chemistry letters, , Mar-25, Volume: 12, Issue:6, 2002
Nucleosides. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase.Journal of medicinal chemistry, , Apr-16, Volume: 36, Issue:8, 1993
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-thJournal of medicinal chemistry, , May-01, Volume: 35, Issue:9, 1992
Synthesis and evaluation of 5-amino-1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine and certain related nucleosides as inhibitors of purine nucleoside phosphorylase.Journal of medicinal chemistry, , Volume: 31, Issue:2, 1988
Inhibitors of human purine nucleoside phosphorylase. Synthesis, purine nucleoside phosphorylase inhibition, and T-cell cytotoxicity of 2,5-diaminothiazolo[5,4-d]pyrimidin-7(6H)-one and 2,5-diaminothiazolo[4,5-d]pyrimidin-7(6H)-one. Two thio isosteres of 8Journal of medicinal chemistry, , Volume: 29, Issue:9, 1986
Synthesis of 8-amino-3-deazaguanine via imidazole precursors. Antitumor activity and inhibition of purine nucleoside phosphorylase.Journal of medicinal chemistry, , Volume: 29, Issue:10, 1986
Stereoelectronic factors in the binding of substrate analogues and inhibitors to purine nucleoside phosphorylase isolated from human erythrocytes.Journal of medicinal chemistry, , Volume: 21, Issue:9, 1978
Enables
This protein enables 7 target(s):
| Target | Category | Definition |
|---|
| nucleoside binding | molecular function | Binding to a nucleoside, a compound consisting of a purine or pyrimidine nitrogenous base linked either to ribose or deoxyribose. [GOC:hjd] |
| purine nucleobase binding | molecular function | Binding to a purine nucleobase, an organic nitrogenous base with a purine skeleton. [GOC:hjd] |
| purine-nucleoside phosphorylase activity | molecular function | Catalysis of the reaction: purine nucleoside + phosphate = purine + alpha-D-ribose 1-phosphate. [EC:2.4.2.1] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| phosphate ion binding | molecular function | Binding to a phosphate ion. [GOC:jl] |
| identical protein binding | molecular function | Binding to an identical protein or proteins. [GOC:jl] |
| guanosine phosphorylase activity | molecular function | Catalysis of the reaction: guanosine + phosphate = guanine + D-ribose 1-phosphate. [EC:2.4.2.15] |
Located In
This protein is located in 6 target(s):
| Target | Category | Definition |
|---|
| extracellular region | cellular component | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. [GOC:go_curators] |
| cytoplasm | cellular component | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684] |
| cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
| secretory granule lumen | cellular component | The volume enclosed by the membrane of a secretory granule. [GOC:rph] |
| extracellular exosome | cellular component | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. [GOC:BHF, GOC:mah, GOC:vesicles, PMID:15908444, PMID:17641064, PMID:19442504, PMID:19498381, PMID:22418571, PMID:24009894] |
| ficolin-1-rich granule lumen | cellular component | Any membrane-enclosed lumen that is part of a ficolin-1-rich granule. [GO_REF:0000064, GOC:TermGenie, PMID:23650620] |
Active In
This protein is active in 1 target(s):
| Target | Category | Definition |
|---|
| cytoplasm | cellular component | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684] |
Involved In
This protein is involved in 14 target(s):
| Target | Category | Definition |
|---|
| allantoin metabolic process | biological process | The chemical reactions and pathways involving allantoin, (2,5-dioxo-4-imidazolidinyl)urea, an intermediate or end product of purine catabolism. [GOC:mah, ISBN:0198547684] |
| nucleobase-containing compound metabolic process | biological process | Any cellular metabolic process involving nucleobases, nucleosides, nucleotides and nucleic acids. [GOC:ai] |
| inosine catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of inosine, hypoxanthine riboside, a nucleoside found free but not in combination in nucleic acids except in the anticodons of some tRNAs. [GOC:go_curators] |
| deoxyinosine catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of deoxyinosine, hypoxanthine deoxyriboside. [GOC:go_curators] |
| deoxyadenosine catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of deoxyadenosine, 2-deoxyribosyladenine, one of the four major nucleosides of DNA. [GOC:go_curators] |
| purine ribonucleoside salvage | biological process | Any process which produces a purine nucleoside from derivatives of it, without de novo synthesis. [GOC:jl] |
| IMP catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of IMP, inosine monophosphate. [ISBN:0198506732] |
| nicotinamide riboside catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of nicotinamide riboside, the product of the formation of a glycosidic bond between ribose and nicotinamide. [ISBN:0198506732] |
| immune response | biological process | Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. [GO_REF:0000022, GOC:add] |
| nucleotide biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of nucleotides, any nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the glycose moiety; may be mono-, di- or triphosphate; this definition includes cyclic-nucleotides (nucleoside cyclic phosphates). [GOC:go_curators] |
| response to xenobiotic stimulus | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc] |
| positive regulation of interleukin-2 production | biological process | Any process that activates or increases the frequency, rate, or extent of interleukin-2 production. [GOC:mah] |
| purine-containing compound salvage | biological process | Any process that generates a purine-containing compound, any nucleobase, nucleoside, nucleotide or nucleic acid that contains a purine base, from derivatives of them without de novo synthesis. [GOC:jl] |
| dAMP catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of dAMP, deoxyadenosine monophosphate (2'-deoxyadenosine 5'-phosphate). [GOC:go_curators] |